Our data that miR-200b effectively reduces proliferation of TNBC cell line (MDA-MB-231), but not luminal subtype breast cancer cells (MCF-7) (Figure 5) suggest that targeting ARRDC3/miR-200b pathway can be more effective in TNBC. Here, ARRDC3 is linked to breast carcinoma.